Showing results (301-310 of 333) with videos related to

Sort By:
Pageof 34
Annals of Hematology|August 17, 2023
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) StudySusanne Isfort, Kirsi Manz, Lino L Teichmann, et al.
Hemasphere|April 25, 2025
Comparing functional and genomic-based precision medicine in blood cancer patientsLukas Kazianka, Alexander Pichler, Christiane Agreiter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow TransplantationKavita Raj, Diderik-Jan Eikema, Donal P McLornan, et al.
Intensive Care Medicine|June 30, 2026
The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosisMichael Ruzicka, Hans Christian Stubbe, Josia Fauser, et al.
European Heart Journal|April 1, 2020
The haemochromatosis gene Hfe and Kupffer cells control LDL cholesterol homeostasis and impact on atherosclerosis developmentEgon Demetz, Piotr Tymoszuk, Richard Hilbe, et al.
Haematologica|November 9, 2023
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.
Blood|March 11, 2025
Clonal hematopoiesis landscape in frequent blood donorsDarja Karpova, Hector Huerga Encabo, Elisa Donato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2022
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical TargetsFlorian Kocher, Alberto Puccini, Gerold Untergasser, et al.
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2022
Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal CancerAndreas Seeber, Francesca Battaglin, Kai Zimmer, et al.
Pageof 34